BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 23, 2024
See today's BioWorld
Home
» Deals and M&As remain level through April; more than a third for COVID-19
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Deals and M&As remain level through April; more than a third for COVID-19
May 22, 2020
By
Karen Carey
No Comments
Of the 160 biopharma deals tracked by
BioWorld
during the month of April, 36% are for collaborations focusing on the development of therapeutics and vaccines for COVID-19.
BioWorld
Analysis and data insight
Coronavirus
